rpmjResearch'n Practical Medicine JournalResearch and Practical Medicine Journal2410-1893"QUASAR", LLC10.17709/2410-1893-2022-9-2-12rpmj-812Research ArticleОбзорыReviewСовременное состояние клинического значения маркеров раннего почечного поврежденияСurrent state of clinical significance of early kidney injury markershttps://orcid.org/0000-0002-3258-8174ХотькоД. Н.KhotkoD. N.

Хотько Дмитрий Николаевич – к.м.н., заведующий отделением урологии. SPIN: 3052-1733, AuthorID: 661608

г. Саратов

Dmitriy N. Khotko – Cand. Sci. (Med.), head of the department of urology. SPIN: 3052-1733, AuthorID: 661608

Saratov

https://orcid.org/0000-0002-4569-9906ХотькоА. И.KhotkoA. I.

Хотько Анастасия Игоревна – к.м.н., ассистент кафедры урологии, научный сотрудник. SPIN: 5095-5145, AuthorID: 1052224, Scopus Author ID: 57212249222

г. Саратов

Anastasiya I. Khotko – Cand. Sci. (Med.), assistant of the department of urology, researcher. SPIN: 5095-5145, AuthorID: 1052224, Scopus Author ID: 57212249222

Saratov

https://orcid.org/0000-0002-3258-8174ТарасенкоА. И.TarasenkoA. I.

Тарасенко Артём Игоревич – к.м.н., заместитель директора по инновационному развитию Института урологии и репродуктивного здоровья. SPIN: 7456-4963, AuthorID: 715646, Scopus Author ID: 57199647114

119991, г. Москва, ул. Трубецкая, д. 8, стр. 2

Artem I. Tarasenko – Cand. Sci. (Med.), deputy director for Innovative development of the Institute of Urology and Reproductive Health. SPIN: 7456-4963, AuthorID: 715646, Scopus Author ID: 57199647114

8/2 Trubetskaya str., Moscow 119991

tar-art@yandex.ruhttps://orcid.org/0000-0002-0548-8231ЕфимоваА. О.EfimovaA. O.

Ефимова Алена Олеговна – к.м.н., врач-дерматовенеролог. SPIN: 6877-0056, AuthorID: 1039569

г. Москва

Alena O. Efimova – Cand. Sci. (Med.), dermatovenerologist. SPIN: 6877-0056, AuthorID: 1039569

Moscow

drleb1990@mail.ruСаратовский ГМУ им. В. И. РазумовскогоРоссияSaratov State Medical University named after V. I. RazumovskyRussian FederationПервый МГМУ им. И. М. Сеченова Минздрава России (Сеченовский Университет)РоссияI. M. Sechenov First Moscow State Medical University (Sechenov University)Russian FederationЦентральный клинический госпиталь ФТС РоссииРоссияCentral Clinical Hospital of the Federal Customs Service of RussiaRussian Federation20220405202292133142Copyright © Хотько Д.Н., Хотько А.И., Тарасенко А.И., Ефимова А.О., 20222022Хотько Д.Н., Хотько А.И., Тарасенко А.И., Ефимова А.О.Khotko D.N., Khotko A.I., Tarasenko A.I., Efimova A.O.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.rpmj.ru/rpmj/article/view/812

Целью обзора являлось отразить современное состояние клинического значения маркеров раннего почечного повреждения у пациентов при мочекаменной болезни.

Выполнен литературный обзор статей (оригинальные исследования и обзоры), опубликованных в период с 2018 г. по февраль 2022 г., посвященных изучению провоспалительных, профибротических и ангиогенных факторов при мочекаменной болезни. Использованы методы библиографического, информационного и семантического поиска источников в базах данных Google Scholar, PubMed, Scopus и Embase.

В настоящее время основными диагностическими маркерами ренальных повреждений принято считать протеинурию или микроальбуминурию, повышение креатинина сыворотки крови и снижение скорости клубочковой фильтрации. Данные показатели широко используются для диагностики степени нарушения почечной функции и выявляют поражение уже на этапе значительного нарушения клубочковой фильтрации, когда процесс поражения практически не обратим. В настоящее время актуальным является поиск биомаркеров острого и хронического почечного повреждения, позволяющих выявлять патологические изменения в почках и определять их характер на ранних этапах диагностики.

Совершенствование диагностических технологий, направленных на детальное представление о патогенезе развития почечной дисфункции у пациентов с мочекаменной болезнью (МКБ), позволит на ранних этапах профилактировать развитие почечной недостаточности у данной категории пациентов.

Study objective was to reflect the current state of the early kidney damage markers clinical significance in patients with urolithiasis. Authors performed a literature review of articles (original studies and reviews) published between 2018 and February 2022 on the study of pro‑inflammatory, profibrotic and angiogenic factors in urolithiasis. Bibliographic, informational and semantic source search methods in Google Scholar, PubMed, Scopus and Embase databases were used. Analysis of a legalistic and systematic sources was carried out.

Proteinuria, serum creatinine and glomerular filtration rate are now accepted as the main diagnostic markers of renal lesions. These markers already allow to reveal lesions at the stage of chronic kidney disease, when the lesion process is practically irreversible. Today it is most relevant to conduct the search for biomarkers of acute and chronic renal lesions at patients with urolithiasis to detect pathological changes in the kidneys and to determine their nature at an early stage of diagnosis.

Improved diagnostic techniques destined to provide a detailed picture of the development of the pathological process in patients with urolithiasis will make it possible to prevent renal failure development at an early stage in this category of patients.

маркеры почечного повреждениямочекаменная болезньбиомаркеры почечной функцииmarkers of renal lesionsurolithiasisbiomarkers of renal functionИсследование выполнено в рамках НИР по государственному заданию Минздрава России №121032900062-0 «Изучение фундаментальных основ этиопатогенеза мочекаменной болезни: роль микробиома мочи и метаболических нарушений в аспекте инфекционных и сердечно-сосудистых осложнений уролитиаза».The study was carried out as research on the state order of the Ministry of Healthcare of the Russian Federation No.121032900062-0 “Study of the fundamental basis for the etiology and pathogenesis of urolithiasis: the significance of the urine microbiome and metabolic disorders in the aspect of infectious and cardiovascular complications of urolithiasis”.ReferencesАкопян Г. Н., Аляев Ю. Г., Рапопорт Л. М., Газимиев М. А., Акопян Г. С. Осложнения перкутанной нефролитотомии: данные литературы и собственные исследования. Вопросы урологии и андрологии. 2017;5(3):28–34. https://doi.org/10.20953/2307‑6631‑2017‑3‑28‑34Akopyan GN, Alyaev YuG, Rapoport LM, Gazimiev MA, Akopyan GS. Complications of percutaneous nephrolithotomy: literature data and original research. Vopr. urol. androl. (Urology and Andrology). 2017;5(3):28–34. (In Russ.). https://doi.org/10.20953/2307‑6631‑2017‑3‑28‑34Буланов Н. М., Серова А. Г., Кузнецова Е. И., Буланова М. Л., Новиков П. И., Козловская Л. В. и др. Молекулы повреждения почечной ткани (KIM‑1, MCP‑1) и коллаген IV типа в оценке активности ассоциированного с антинейтрофильными цитоплазматическими антителами гломерулонефрита. Терапевтический архив. 2017;89(6):48–55. https://doi.org/10.17116/terarkh201789648‑55Bulanov NM, Serova AG, Kuznetsova EI, Bulanova ML, Novikov PI, Kozlovskaia LV, et al. Kidney injury molecules (KIM‑1, MCP‑1) and type IV collagen in the assessment of activity of antineutrophil cytoplasmic antibody‑associated glomerulonephritis. Terapevticheskii Arkhiv. 2017;89(6):48–55. (In Russ.). https://doi.org/10.17116/terarkh201789648‑55Евдокимова А. Г., Рыжова Ю. В. Кардио‑и нефропротективные эффекты современной антигипертензивной терапии. CardioСоматика. 2017; 8(1):24.Evdokimova AG, Ryzhova YuV. Cardio‑and nephroprotective effects of modern antihypertensive therapy. CardioSomatics. 2017; 8(1):24. (In Russ.).Макарова Т. П., Ишбулдина А. В. Роль цитокинов в прогрессировании хронической болезни почек у детей. Российский вестник перинатологии и педиатрии. 2021;66(4):25–31. https://doi.org/10.21508/1027‑4065‑2021‑66‑4‑25‑31Makarova TP, Ishbuldina AV. Cytokines and progressive chronic kidney disease in children. Rossiyskiy Vestnik Perinatologii i Pediatrii (Russian Bulletin of Perinatology and Pediatrics). 2021;66(4):25–31. (In Russ.) https://doi.org/10.21508/1027‑4065‑2021‑66‑4‑25‑31Подзолков В. И., Брагина А. Е., Дружинина Н. А. Прогностическая значимость маркеров эндотелиальной дисфункции у больных гипертонической болезнью. Российский кардиологический журнал. 2018;(4):7–13. https://doi.org/10.15829/1560‑4071‑2018‑4‑7‑13Podzolkov VI, Bragina AE, Bragina NA. Prognostic significance of endothelial dysfunction markers in arterial hypertension. Russian Journal of Cardiology. 2018;(4):7–13. (In Russ.). https://doi.org/10.15829/1560‑4071‑2018‑4‑7‑13Жуманазаров С. Б., Жаббаров А. А., Мирзаева Г. П., Эшонов Ш. Н., Бобокулов М. Б. Прогностическое значение клинико‑патогенетических особенностей развития хронической болезни почек вследствие гломерулярных заболеваний. Central Asian Journal of Medical and Natural Sciences. 2021; 2(2):175–184.Zhumanazarov SB, Jabbarov AA, Mirzoeva GP, Eshonov ShN, Bobokulov MB. Prognostic significance of clinical and pathogenetic features of the development of chronic kidney disease due to glomerular diseases. Central Asian Journal of Medical and Natural Sciences. 2021; 2(2):175–184. (In Russ.).Саенко В. С., Песегов С. В., Вовденко С. В. Современный взгляд на механизмы образования мочевых камней и принципы общей метафилактики мочекаменной болезни. Справочник поликлинического врача. 2018;(1):33–38.Saenko VS, Pesegov SV, Vovdenko SV. A modern view on the mechanisms of formation of urinary stones and the principles of general metaphylaxis of urolithiasis. Reference Book of the Polyclinic Doctor. 2018;(1):33–38. (In Russ.).Хотько А. И., Хотько Д. Н., Захарова Н. Б., Тарасенко А. И., Попков В. М., Алексеев А. В. Эффективность блокатора кальциевых каналов лерканидипина в качестве нефропротектора при лечении больных уролитиазом с обструктивным синдромом и мониторинг цитокинового профиля крови. Урология. 2019;(5):48–52. https://doi.org/10.18565/urology.2019.5.48‑52Khotko AI, Khotko DN, Zakharova NB, Tarasenko AI, Popkov VM, Alekseev AV. Nephroprotective effect of calcium channel blocker lercanidipine in treatment of patients with urolithiasis and urinary tract obstruction and monitoring of the serum cytokine profile. Urology. 2019;(5):48–52. (In Russ.). https://doi.org/10.18565/urology.2019.5.48‑52Швецов М. Ю. Хроническая болезнь почек как общемедицинская проблема: современные принципы нефропрофилактики и нефропротективной терапии. Consilium Medicum. 2014;16(7):51–64.Shvetsov MYu. Chronic kidney disease as a general medical problem: modern principles of nephroprophylaxis and nephroprotective therapy. Consilium Medicum. 2014;16(7):51–64. (In Russ.).Alazouny ZM, Alghonamy NM, Mohamed SR, Abdel Aal SM. Mesenchymal stem cells microvesicles versus granulocytes colony stimulating factor efficacy in ameliorating septic induced acute renal cortical injury in adult male albino rats (Histological and Immunohistochemical Study). Ultrastruct Pathol. 2022 Mar 4;46(2):164–187. https://doi.org/10.1080/01913123.2022.2039826Alazouny ZM, Alghonamy NM, Mohamed SR, Abdel Aal SM. Mesenchymal stem cells microvesicles versus granulocytes colony stimulating factor efficacy in ameliorating septic induced acute renal cortical injury in adult male albino rats (Histological and Immunohistochemical Study). Ultrastruct Pathol. 2022 Mar 4;46(2):164–187. https://doi.org/10.1080/01913123.2022.2039826Amin AP, Salisbury AC, McCullough PA, Gosch K, Spertus JA, Venkitachalam L, et al. Trends in the incidence of acute kidney injury in patients hospitalized with acute myocardial infarction. Arch Intern Med. 2012 Feb 13;172(3):246–253. https://doi.org/10.1001/archinternmed.2011.1202Amin AP, Salisbury AC, McCullough PA, Gosch K, Spertus JA, Venkitachalam L, et al. Trends in the incidence of acute kidney injury in patients hospitalized with acute myocardial infarction. Arch Intern Med. 2012 Feb 13;172(3):246–253. https://doi.org/10.1001/archinternmed.2011.1202Aranda‑Rivera AK, Cruz‑Gregorio A, Aparicio‑Trejo OE, Ortega‑Lozano AJ, Pedraza‑Chaverri J. Redox signaling pathways in unilateral ureteral obstruction (UUO)‑induced renal fibrosis. Free Radic Biol Med. 2021 Aug 20;172:65–81. https://doi.org/10.1016/j.freeradbiomed.2021.05.034Aranda‑Rivera AK, Cruz‑Gregorio A, Aparicio‑Trejo OE, Ortega‑Lozano AJ, Pedraza‑Chaverri J. Redox signaling pathways in unilateral ureteral obstruction (UUO)‑induced renal fibrosis. Free Radic Biol Med. 2021 Aug 20;172:65–81. https://doi.org/10.1016/j.freeradbiomed.2021.05.034Chen TK, Estrella MM, Appel LJ, Coresh J, Luo S, Obeid W, et al. Serum levels of IL‑6, IL‑8 and IL‑10 and risks of end‑stage kidney disease and mortality. Nephrol Dial Transplant. 2021 Feb 20;36(3):561–563. https://doi.org/10.1093/ndt/gfaa260Chen TK, Estrella MM, Appel LJ, Coresh J, Luo S, Obeid W, et al. Serum levels of IL‑6, IL‑8 and IL‑10 and risks of end‑stage kidney disease and mortality. Nephrol Dial Transplant. 2021 Feb 20;36(3):561–563. https://doi.org/10.1093/ndt/gfaa260Courbebaisse M, Prot‑Bertoye C, Bertocchio JP, Baron S, Maruani G, Briand S, et al. Nephrolithiasis of adult: From mechanisms to preventive medical treatment. Rev Med Interne. 2017 Jan;38(1):44–52. https://doi.org/10.1016/j.revmed.2016.05.013Courbebaisse M, Prot‑Bertoye C, Bertocchio JP, Baron S, Maruani G, Briand S, et al. Nephrolithiasis of adult: From mechanisms to preventive medical treatment. Rev Med Interne. 2017 Jan;38(1):44–52. https://doi.org/10.1016/j.revmed.2016.05.013D'Costa M, Savcic‑Kos R, Huang J, Rule AD, Murali N. Urological Procedures in Urolithiasis and Their Association with Chronic Kidney Disease. Clin Med Res. 2016 Jun;14(2):75–82. https://doi.org/10.3121/cmr.2016.1261D'Costa M, Savcic‑Kos R, Huang J, Rule AD, Murali N. Urological Procedures in Urolithiasis and Their Association with Chronic Kidney Disease. Clin Med Res. 2016 Jun;14(2):75–82. https://doi.org/10.3121/cmr.2016.1261Endre ZH, Pickering JW, Walker RJ. Clearance and beyond: the complementary roles of GFR measurement and injury biomarkers in acute kidney injury (AKI). Am J Physiol Renal Physiol. 2011 Oct;301(4):F697–707. https://doi.org/10.1152/ajprenal.00448.2010Endre ZH, Pickering JW, Walker RJ. Clearance and beyond: the complementary roles of GFR measurement and injury biomarkers in acute kidney injury (AKI). Am J Physiol Renal Physiol. 2011 Oct;301(4):F697–707. https://doi.org/10.1152/ajprenal.00448.2010Matlaga BR, Krambeck AE, Lingeman JE. Surgical Management of Upper Urinary Tract Calculi. In: Wein AJ, Kavoussi LR, Partin AW, Peters CA. Campbell‑Walsh Urology. Eleventh Edition. Elsevier Inc; 2016;1260–1287.Matlaga BR, Krambeck AE, Lingeman JE. Surgical Management of Upper Urinary Tract Calculi. In: Wein AJ, Kavoussi LR, Partin AW, Peters CA. Campbell‑Walsh Urology. Eleventh Edition. Elsevier Inc; 2016;1260–1287.Ozer JS, Dieterle F, Troth S, Perentes E, Cordier A, Verdes P, et al. A panel of urinary biomarkers to monitor reversibility of renal injury and a serum marker with improved potential to assess renal function. Nat Biotechnol. 2010 May;28(5):486–494. https://doi.org/10.1038/nbt.1627Ozer JS, Dieterle F, Troth S, Perentes E, Cordier A, Verdes P, et al. A panel of urinary biomarkers to monitor reversibility of renal injury and a serum marker with improved potential to assess renal function. Nat Biotechnol. 2010 May;28(5):486–494. https://doi.org/10.1038/nbt.1627Goldfarb DS. Empiric therapy for kidney stones. Urolithiasis. 2019 Feb;47(1):107–113. https://doi.org/10.1007/s00240‑018‑1090‑6Goldfarb DS. Empiric therapy for kidney stones. Urolithiasis. 2019 Feb;47(1):107–113. https://doi.org/10.1007/s00240‑018‑1090‑6Haase M, Devarajan P, Haase‑Fielitz A, Bellomo R, Cruz DN, Wagener G, et al. The outcome of neutrophil gelatinase‑associated lipocalin‑positive subclinical acute kidney injury: a multicenter pooled analysis of prospective studies. J Am Coll Cardiol. 2011 Apr 26;57(17):1752–1761. https://doi.org/10.1016/j.jacc.2010.11.051Haase M, Devarajan P, Haase‑Fielitz A, Bellomo R, Cruz DN, Wagener G, et al. The outcome of neutrophil gelatinase‑associated lipocalin‑positive subclinical acute kidney injury: a multicenter pooled analysis of prospective studies. J Am Coll Cardiol. 2011 Apr 26;57(17):1752–1761. https://doi.org/10.1016/j.jacc.2010.11.051Hsu L, Li H, Pucheril D, Hansen M, Littleton R, Peabody J, et al. Use of percutaneous nephrostomy and ureteral stenting in management of ureteral obstruction. World J Nephrol. 2016 Mar 6;5(2):172–181. https://doi.org/10.5527/wjn.v5.i2.172Hsu L, Li H, Pucheril D, Hansen M, Littleton R, Peabody J, et al. Use of percutaneous nephrostomy and ureteral stenting in management of ureteral obstruction. World J Nephrol. 2016 Mar 6;5(2):172–181. https://doi.org/10.5527/wjn.v5.i2.172Jing J, Zhong X, Liu BC, Lyu LL. Research progress of vascular endothelial growth factor‑A and its isoforms in kidney disease. Sheng Li Xue Bao. 2022 Feb 25;74(1):59–66.Jing J, Zhong X, Liu BC, Lyu LL. Research progress of vascular endothelial growth factor‑A and its isoforms in kidney disease. Sheng Li Xue Bao. 2022 Feb 25;74(1):59–66.Madsen MG. Urinary biomarkers in hydronephrosis. Dan Med J. 2013 Feb;60(2):B4582.Madsen MG. Urinary biomarkers in hydronephrosis. Dan Med J. 2013 Feb;60(2):B4582.Merrikhi AR, Keivanfar M, Gheissari A, Mousavinasab F. Urine interlukein‑8 as a diagnostic test for vesicoureteral reflux in children. J Pak Med Assoc. 2012 Mar;62(3 Suppl 2):S52–54.Merrikhi AR, Keivanfar M, Gheissari A, Mousavinasab F. Urine interlukein‑8 as a diagnostic test for vesicoureteral reflux in children. J Pak Med Assoc. 2012 Mar;62(3 Suppl 2):S52–54.Pathak S. Upper Urinary Tract Obstruction. Basic Urological Sciences. CRC Press. 2021, 131–137 p.Pathak S. Upper Urinary Tract Obstruction. Basic Urological Sciences. CRC Press. 2021, 131–137 p.Ramsey S, Robertson A, Ablett MJ, Meddings RN, Hollins GW, Little B. Evidence‑based drainage of infected hydronephrosis secondary to ureteric calculi. J Endourol. 2010 Feb;24(2):185–189. https://doi.org/10.1089/end.2009.0361Ramsey S, Robertson A, Ablett MJ, Meddings RN, Hollins GW, Little B. Evidence‑based drainage of infected hydronephrosis secondary to ureteric calculi. J Endourol. 2010 Feb;24(2):185–189. https://doi.org/10.1089/end.2009.0361Sayer JA. Progress in Understanding the Genetics of Calcium‑Containing Nephrolithiasis. J Am Soc Nephrol. 2017 Mar;28(3):748–759. https://doi.org/10.1681/ASN.2016050576Sayer JA. Progress in Understanding the Genetics of Calcium‑Containing Nephrolithiasis. J Am Soc Nephrol. 2017 Mar;28(3):748–759. https://doi.org/10.1681/ASN.2016050576Perazella MA, Coca SG. Traditional urinary biomarkers in the assessment of hospital‑acquired AKI. Clin J Am Soc Nephrol. 2012 Jan;7(1):167–174. https://doi.org/10.2215/CJN.09490911Perazella MA, Coca SG. Traditional urinary biomarkers in the assessment of hospital‑acquired AKI. Clin J Am Soc Nephrol. 2012 Jan;7(1):167–174. https://doi.org/10.2215/CJN.09490911Simmons EM, Himmelfarb J, Sezer MT, Chertow GM, Mehta RL, Paganini EP, et al. Plasma cytokine levels predict mortality in patients with acute renal failure. Kidney Int. 2004 Apr;65(4):1357–1365. https://doi.org/10.1111/j.1523‑1755.2004.00512.xSimmons EM, Himmelfarb J, Sezer MT, Chertow GM, Mehta RL, Paganini EP, et al. Plasma cytokine levels predict mortality in patients with acute renal failure. Kidney Int. 2004 Apr;65(4):1357–1365. https://doi.org/10.1111/j.1523‑1755.2004.00512.xSilverstein DM, Travis BR, Thornhill BA, Schurr JS, Kolls JK, Leung JC, et al. Altered expression of immune modulator and structural genes in neonatal unilateral ureteral obstruction. Kidney Int. 2003 Jul;64(1):25–35. https://doi.org/10.1046/j.1523‑1755.2003.00067.xSilverstein DM, Travis BR, Thornhill BA, Schurr JS, Kolls JK, Leung JC, et al. Altered expression of immune modulator and structural genes in neonatal unilateral ureteral obstruction. Kidney Int. 2003 Jul;64(1):25–35. https://doi.org/10.1046/j.1523‑1755.2003.00067.xWang CJ, Hsu CS, Chen HW, Chang CH, Tsai PC. Percutaneous nephrostomy versus ureteroscopic management of sepsis associated with ureteral stone impaction: a randomized controlled trial. Urolithiasis. 2016 Oct;44(5):415–459. https://doi.org/10.1007/s00240‑015‑0852‑7Wang CJ, Hsu CS, Chen HW, Chang CH, Tsai PC. Percutaneous nephrostomy versus ureteroscopic management of sepsis associated with ureteral stone impaction: a randomized controlled trial. Urolithiasis. 2016 Oct;44(5):415–459. https://doi.org/10.1007/s00240‑015‑0852‑7Waring WS, Moonie A. Earlier recognition of nephrotoxicity using novel biomarkers of acute kidney injury. Clin Toxicol (Phila). 2011 Oct;49(8):720–728. https://doi.org/10.3109/15563650.2011.615319Waring WS, Moonie A. Earlier recognition of nephrotoxicity using novel biomarkers of acute kidney injury. Clin Toxicol (Phila). 2011 Oct;49(8):720–728. https://doi.org/10.3109/15563650.2011.615319Zhou J, Li R, Liu Q, Zhang J, Huang H, Huang C, et al. Blocking 5‑LO pathway alleviates renal fibrosis by inhibiting the epithelial‑mesenchymal transition. Biomed Pharmacother. 2021 Jun;138:111470. https://doi.org/10.1016/j.biopha.2021.111470Zhou J, Li R, Liu Q, Zhang J, Huang H, Huang C, et al. Blocking 5‑LO pathway alleviates renal fibrosis by inhibiting the epithelial‑mesenchymal transition. Biomed Pharmacother. 2021 Jun;138:111470. https://doi.org/10.1016/j.biopha.2021.111470

The authors declare that there are no conflicts of interest present.